Research focus: a novel pan-lysyl oxidase inhibitor for improving the treatment of pancreatic cancer

Dr. Jessica Chitty and Dr. Thomas Cox generated and validated a novel selective and irreversible pan-lysyl oxidase inhibitor: PXS-5505. Their experiments in a series of pre-clinical models show that by acting on the tumour microenvironment, this small molecule drug has the ability to significantly enhance chemotherapy efficacy.

Listen to this episode to find out direct from the authors about the effects that PXS-5505 in combination with gemcetabine has on tumour morphology, behaviour and subject survival in pancreatic cancer.

This study has been published in Nature Cancer and was included in the EACR's Highlights in Cancer Research, a summary of the most interesting and impactful recent papers in cancer research.